EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases
- 30 November 2011
- journal article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (6), 380-386
- https://doi.org/10.1016/j.cllc.2011.02.006
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare
- National Research Foundation of Korea
- Chonbuk National University Hospital
- Ministry of Education, Science and Technology (2010-0001730)
This publication has 34 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary TumorsClinical Cancer Research, 2009
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBritish Journal of Cancer, 2008
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinibBritish Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Metastasis genes: A progression puzzleNature, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002